NEBUPENT (pentamidine isethionate) by Fresenius Kabi is clinical pharmacology: microbiology mechanism of action studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of dna, rna, phospholipid and protein synthesis. First approved in 1989.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
NEBUPENT is an inhaled pentamidine isethionate solution indicated for Pneumocystis jiroveci pneumonia (PJP) prophylaxis and treatment in immunocompromised patients, primarily those with AIDS. The drug interferes with microbial nuclear metabolism by inhibiting DNA, RNA, phospholipid, and protein synthesis. It delivers high local lung concentrations via aerosol administration while maintaining minimal systemic exposure.
Product is nearing loss of exclusivity with limited commercial momentum; teams are likely focused on generic mitigation and niche market retention rather than expansion.
CLINICAL PHARMACOLOGY: Microbiology Mechanism of Action Studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis. However, the mode of action is not fully understood. Activity in vitro and in vivo…
Worked on NEBUPENT at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNEBUPENT offers limited career growth given its LOE-approaching lifecycle and minimal linked job postings; roles are primarily defensive (protecting market share, managing generic transition, reimbursement). Career mobility may be constrained unless moving into specialty generics or niche market management.